Does the media refer more to VRDN or CELC?

In the previous week, Celcuity had 16 more articles in the media than Viridian Therapeutics. MarketBeat recorded 19 mentions for Celcuity and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Celcuity's score of -0.13 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral

Does the media prefer HIMS or VRDN?

In the previous week, Hims & Hers Health had 20 more articles in the media than Viridian Therapeutics. MarketBeat recorded 23 mentions for Hims & Hers Health and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Hims & Hers Health's score of 0.84 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 7 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or PACS?

In the previous week, Viridian Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 3 mentions for Viridian Therapeutics and 1 mentions for PACS Group. Viridian Therapeutics' average media sentiment score of 0.88 beat PACS Group's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VRDN or CAI?

In the previous week, Caris Life Sciences had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Caris Life Sciences' score of 0.40 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VRDN or BLLN?

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 3 articles in the media. Billiontoone's average media sentiment score of 1.09 beat Viridian Therapeutics' score of 0.88 indicating that Billiontoone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$16.35 +0.48 (+3.02%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$16.48 +0.13 (+0.79%)

As of 06/3/2026 07:55 PM Eastern

Compare

VRDN vs. CELC, HIMS, PACS, CAI, and BLLN

Should you buy Viridian Therapeutics stock or one of its competitors? MarketBeat compares Viridian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viridian Therapeutics include Celcuity (CELC), Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Viridian Therapeutics compare to Celcuity?

Viridian Therapeutics (NASDAQ:VRDN) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Celcuity has lower revenue, but higher earnings than Viridian Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Viridian Therapeutics currently has a consensus target price of $36.14, indicating a potential upside of 121.06%. Celcuity has a consensus target price of $152.09, indicating a potential upside of 70.98%. Given Viridian Therapeutics' higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Celcuity has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Viridian Therapeutics' return on equity of -80.19% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Celcuity	N/A	-244.61%	-50.22%

63.3% of Celcuity shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Celcuity had 16 more articles in the media than Viridian Therapeutics. MarketBeat recorded 19 mentions for Celcuity and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Celcuity's score of -0.13 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Neutral

Viridian Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

Summary

Viridian Therapeutics beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, Hims & Hers Health had 20 more articles in the media than Viridian Therapeutics. MarketBeat recorded 23 mentions for Hims & Hers Health and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Hims & Hers Health's score of 0.84 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	7 Very Positive mention(s)	8 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hims & Hers Health has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Hims & Hers Health currently has a consensus price target of $28.70, suggesting a potential upside of 4.40%. Viridian Therapeutics has a consensus price target of $36.14, suggesting a potential upside of 121.06%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.71	$128.37M	-$0.09	N/A
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A

Hims & Hers Health has a net margin of -0.56% compared to Viridian Therapeutics' net margin of -490.31%. Hims & Hers Health's return on equity of 6.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Summary

Hims & Hers Health beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to PACS Group?

Viridian Therapeutics (NASDAQ:VRDN) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

PACS Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A
PACS Group	$5.29B	1.09	$191.54M	$1.56	23.39

PACS Group has a net margin of 4.49% compared to Viridian Therapeutics' net margin of -490.31%. PACS Group's return on equity of 26.47% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
PACS Group	4.49%	26.47%	4.36%

In the previous week, Viridian Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 3 mentions for Viridian Therapeutics and 1 mentions for PACS Group. Viridian Therapeutics' average media sentiment score of 0.88 beat PACS Group's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics currently has a consensus target price of $36.14, suggesting a potential upside of 121.06%. PACS Group has a consensus target price of $48.00, suggesting a potential upside of 31.55%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

PACS Group beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Caris Life Sciences?

Viridian Therapeutics (NASDAQ:VRDN) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Caris Life Sciences has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A
Caris Life Sciences	$812.03M	5.39	-$68.09M	-$7.61	N/A

In the previous week, Caris Life Sciences had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.88 beat Caris Life Sciences' score of 0.40 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caris Life Sciences has a net margin of 3.75% compared to Viridian Therapeutics' net margin of -490.31%. Caris Life Sciences' return on equity of 98.28% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Caris Life Sciences	3.75%	98.28%	48.87%

Viridian Therapeutics presently has a consensus price target of $36.14, suggesting a potential upside of 121.06%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 78.01%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Caris Life Sciences beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Billiontoone?

Viridian Therapeutics (NASDAQ:VRDN) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Viridian Therapeutics presently has a consensus price target of $36.14, indicating a potential upside of 121.06%. Billiontoone has a consensus price target of $125.29, indicating a potential upside of 27.37%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Viridian Therapeutics and Viridian Therapeutics both had 3 articles in the media. Billiontoone's average media sentiment score of 1.09 beat Viridian Therapeutics' score of 0.88 indicating that Billiontoone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Billiontoone has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Billiontoone's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Billiontoone	N/A	N/A	N/A

Billiontoone has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	23.79	-$342.60M	-$3.32	N/A
Billiontoone	$305.11M	14.83	$7.45M	$0.55	178.84

Summary

Billiontoone beats Viridian Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.64B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-4.92	17.78	22.39	24.18
Price / Sales	23.79	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	2.65	6.63	9.84	6.72
Net Income	-$342.60M	$24.20M	$3.57B	$337.19M
7 Day Performance	-6.30%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	15.55%	45.50%	26.49%	33.10%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.9591 of 5 stars	$16.35 +3.0%	$36.14 +121.1%	+13.1%	$1.64B	$70.85M	N/A	50
CELC Celcuity	3.1103 of 5 stars	$122.96 -7.5%	$150.27 +22.2%	+645.0%	$6.48B	N/A	N/A	40	Trending News Analyst Forecast Gap Down
HIMS Hims & Hers Health	2.9239 of 5 stars	$27.77 +6.2%	$28.70 +3.3%	-49.8%	$6.05B	$2.35B	N/A	2,442	Trending News Gap Down
PACS PACS Group	3.6933 of 5 stars	$35.55 -3.0%	$48.00 +35.0%	+258.4%	$5.80B	$5.43B	22.79	47,455
CAI Caris Life Sciences	4.7619 of 5 stars	$16.45 -1.6%	$27.56 +67.5%	N/A	$4.73B	$812.03M	N/A	1,846	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. CELC, HIMS, PACS, CAI, and BLLN

How does Viridian Therapeutics compare to Celcuity?

Summary

How does Viridian Therapeutics compare to Hims & Hers Health?

Summary

How does Viridian Therapeutics compare to PACS Group?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. CELC, HIMS, PACS, CAI, and BLLN

How does Viridian Therapeutics compare to Celcuity?

Which has preferable earnings & valuation, VRDN or CELC?

Do analysts prefer VRDN or CELC?

Is VRDN or CELC more profitable?

Do institutionals and insiders have more ownership in VRDN or CELC?

Does the media refer more to VRDN or CELC?

Which has more volatility and risk, VRDN or CELC?

Summary

How does Viridian Therapeutics compare to Hims & Hers Health?

Does the media prefer HIMS or VRDN?

Do institutionals and insiders have more ownership in HIMS or VRDN?

Which has more risk and volatility, HIMS or VRDN?

Do analysts rate HIMS or VRDN?

Which has stronger earnings and valuation, HIMS or VRDN?

Is HIMS or VRDN more profitable?

Summary

How does Viridian Therapeutics compare to PACS Group?

Which has better earnings and valuation, VRDN or PACS?

Is VRDN or PACS more profitable?

Does the media refer more to VRDN or PACS?

Do analysts recommend VRDN or PACS?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Which has higher earnings & valuation, VRDN or CAI?

Does the media prefer VRDN or CAI?

Is VRDN or CAI more profitable?

Do analysts recommend VRDN or CAI?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Do analysts rate VRDN or BLLN?

Does the media refer more to VRDN or BLLN?

Is VRDN or BLLN more profitable?

Which has better valuation and earnings, VRDN or BLLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools